Veracyte (VCYT) FY Earnings Call Presentation

Financial Performance - Veracyte achieved total revenue of $446 million in 2024[21] - The company experienced a 28% growth in testing revenue in 2024[21] - GAAP Net Income for 2024 was $24 million[21] - Adjusted EBITDA margin for 2024 was 20.6%[21] Key Products and Market Position - Decipher is a market leader in molecular diagnostics for prostate cancer prognosis and prediction, with over 275,000 patients tested to date[24] - Decipher saw a 37% volume growth and 33% revenue growth in Q1 2025[24] - Afirma is a market leader in molecular thyroid diagnostics, with over 350,000 patients tested to date[31] - Afirma volume grew by 10% and revenue grew by 6% in Q1 2025[31] Future Products and Expansion - Prosigna LDT is under development for breast cancer, expected to be commercially available in mid-2026[37] - The company plans to launch MRD testing for muscle invasive bladder cancer (MIBC) in the first half of 2026[39]